A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
Status:
Completed
Trial end date:
2018-11-10
Target enrollment:
Participant gender:
Summary
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can
prevent platelets from binding together. This study will also help to find out more about the
safety of this new drug. The drug selatogrel (ACT-246475) will be used in 2 different doses
(8 mg or 16 mg) and will be administered in the thigh.